Small, Trudy N <br/><br/>
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.  [electronic resource] 

 -  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation  Feb 2007 
 - 235-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1083-8791 
<br/><br/><label>Standard No.: </label>10.1016/j.bbmt.2006.10.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Busulfan--administration & dosage<br/>Child<br/>Child, Preschool<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Histocompatibility Testing<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Infant<br/>Leukemia, Myeloid, Acute--therapy<br/>Male<br/>Melphalan--administration & dosage<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Myelodysplastic Syndromes--therapy<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--therapy<br/>Prospective Studies<br/>Survival Analysis<br/>Tacrolimus--administration & dosage<br/>Transplantation Conditioning--methods